Search results for: Indication-Based Pricing
Filter search results
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
…indications? Indication-based pricing (IBP) has been proposed as a way to tackle this issue, permitting price to vary according to indication and – critically – according to value. The notion…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
28 October 2015
…OHE Briefing on the topic of multi-indication pricing. The briefing contains a summary of a workshop organised and facilitated by OHE and MME Europe. Multi-indication pricing (MIP) involves setting a…
Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
1 July 2018
…term theory suggests that indication-based pricing can improve overall welfare if it means greater patient access, but payers may face higher expenditure. However, the potential longer-term (dynamic) effects of IBP…
Multi-indication Pricing: Pros, Cons and Applicability to the UK
1 October 2015
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent…
OHE at the ISPOR Summit on New Approaches to Value Assessment: Towards More Informed Pricing in Healthcare October, 2018
5 November 2018
…presented on Indication Based Pricing: A better way to value drugs? setting out the arguments for and against differential pricing by indication. This built on work from an OHE consulting…
Assessing the Life-cycle Value of Second-generation Antipsychotics in Sweden and the UK
17 July 2019
…A. & Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics. Available at: https://www.ohe.org/publications/indication-based-pricing-ibp-discussion-paper-should-drug-prices-differ-indication Lakdawalla, D., MacEwan, J.P., Dubois, R., Westrich, K., Berdud,…
OHE at ISPOR Europe 2018
…Value Based Pricing Versus WHO Fair Pricing. Which Delivers Universal Health Coverage? The World Health Organisation (WHO) is arguing that value-based pricing alone is not a viable basis for the…
Reflections from Adrian Towse on decades of HEOR research and impact
11 November 2025
…pricing increasing utilisation of on-patent drugs at prices reflecting local value-for-money considerations. I then applied this same conceptual approach to the need for indication-based pricing for the same drug, and to…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
1 March 2015
A new OHE Consulting Report considers the data capabilities in the UK for monitoring medicine use according to indication using real world data. A new OHE Consulting Report considers the…